Quality

  1. Home
  2. Products
  3. Customized ADCs
  4. TNFRSF10A
  5. Anti-TNFRSF10A (Mapatumumab)-MC-Vc-PAB-SN38 ADC

Anti-TNFRSF10A (Mapatumumab)-MC-Vc-PAB-SN38 ADC (ADC-W-2418)

This ADC product is comprised of an anti-TNFRSF10A monoclonal antibody conjugated via a MC-Vc-PAB linker to SN38. The SN-38 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, SN-38 binds to DNA, causes DNA damage.

 ADC Target

  • Name
  • TNFRSF10A
  • Alternative Names
  • TNFRSF10A; tumor necrosis factor receptor superfamily, member 10a; tumor necrosis factor receptor superfamily member 10A; Apo2; CD261; DR4; TRAILR 1; TRAIL-R1; TRAIL receptor 1; death receptor 4; cytotoxic TRAIL receptor; TNF-related apoptosis-inducing ligand receptor 1; tumor necrosis factor receptor superfamily member 10a variant 2; APO2; TRAILR1; TRAILR-1; MGC9365;
  • Target Entrez Gene ID
  • 8797
  • Overview
  • The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptor is activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL), and thus transduces cell death signal and induces cell apoptosis. Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by this protein.

 ADC Antibody

  • Overview
  • Human Anti-TNFRSF10A IgG1 antibody, Mapatumumab
  • Generic name
  • Mapatumumab
  • Host animal
  • Human

 ADC Linker

  • Name
  • MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl)
  • Description
  • Peptide linkers, belonging to Enzymatically cleavable linkers, combine greater systemic stability with rapid enzymatic release of the drug in the target cell. The scission of peptidic bonds relies on lysosomal proteolytic enzymes, which have very low activities in blood due to endogenous inhibitors and the unfavorably high pH value of blood.

 ADC payload drug

  • Name
  • SN-38 (7-ethyl-10-hydroxycamptothecin)
  • Description
  • SN38 (7-ethyl-10-hydroxy camptothecin) is an active metabolite of the cancer prodrug, irinotecan, with the ability of inhibiting Topoisomerase I, which is belong to the camptothecin family. SN-38 is formed via hydrolysis of irinotecan by carboxylesterases and metabolized via glucuronidation by UGT1A1.

For Research Use Only. NOT FOR CLINICAL USE.

Related Products

Online Inquiry
Name:
*Phone:
*E-mail Address:
*Products or Services Interested:
Company/Institution
Project Description:









Customized FluoroAb™

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.

Contact us
USA
 
 Tel:
 Fax:
 Email:
Europe
 
 Tel:
 Email:
Germany
 
 Tel:
 Email:


Inquiry

Top